dc.contributor.author | Martin, L-A | |
dc.contributor.author | Ribas, R | |
dc.contributor.author | Simigdala, N | |
dc.contributor.author | Schuster, E | |
dc.contributor.author | Pancholi, S | |
dc.contributor.author | Tenev, T | |
dc.contributor.author | Gellert, P | |
dc.contributor.author | Buluwela, L | |
dc.contributor.author | Harrod, A | |
dc.contributor.author | Thornhill, A | |
dc.contributor.author | Nikitorowicz-Buniak, J | |
dc.contributor.author | Bhamra, A | |
dc.contributor.author | Turgeon, M-O | |
dc.contributor.author | Poulogiannis, G | |
dc.contributor.author | Gao, Q | |
dc.contributor.author | Martins, V | |
dc.contributor.author | Hills, M | |
dc.contributor.author | Garcia-Murillas, I | |
dc.contributor.author | Fribbens, C | |
dc.contributor.author | Patani, N | |
dc.contributor.author | Li, Z | |
dc.contributor.author | Sikora, MJ | |
dc.contributor.author | Turner, N | |
dc.contributor.author | Zwart, W | |
dc.contributor.author | Oesterreich, S | |
dc.contributor.author | Carroll, J | |
dc.contributor.author | Ali, S | |
dc.contributor.author | Dowsett, M | |
dc.date.accessioned | 2017-10-24T10:45:53Z | |
dc.date.issued | 2017-11-30 | |
dc.identifier.citation | Nature communications, 2017, 8 (1), pp. 1865 - ? | |
dc.identifier.issn | 2041-1723 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/871 | |
dc.identifier.eissn | 2041-1723 | |
dc.identifier.doi | 10.1038/s41467-017-01864-y | |
dc.description.abstract | Resistance to endocrine therapy remains a major clinical problem in breast cancer. Genetic studies highlight the potential role of estrogen receptor-α (ESR1) mutations, which show increased prevalence in the metastatic, endocrine-resistant setting. No naturally occurring ESR1 mutations have been reported in in vitro models of BC either before or after the acquisition of endocrine resistance making functional consequences difficult to study. We report the first discovery of naturally occurring ESR1 Y537C and ESR1 Y537S mutations in MCF7 and SUM44 ESR1-positive cell lines after acquisition of resistance to long-term-estrogen-deprivation (LTED) and subsequent resistance to fulvestrant (ICIR). Mutations were enriched with time, impacted on ESR1 binding to the genome and altered the ESR1 interactome. The results highlight the importance and functional consequence of these mutations and provide an important resource for studying endocrine resistance. | |
dc.format | Electronic | |
dc.format.extent | 1865 - ? | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | NATURE PORTFOLIO | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | Cell Line, Tumor | |
dc.subject | Humans | |
dc.subject | Breast Neoplasms | |
dc.subject | Tamoxifen | |
dc.subject | Estradiol | |
dc.subject | Selective Estrogen Receptor Modulators | |
dc.subject | Estrogen Receptor alpha | |
dc.subject | Drug Resistance, Neoplasm | |
dc.subject | Mutation | |
dc.subject | Female | |
dc.subject | MCF-7 Cells | |
dc.subject | Estrogen Receptor Antagonists | |
dc.subject | Fulvestrant | |
dc.title | Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2017-10-20 | |
rioxxterms.funder | The Institute of Cancer Research | |
rioxxterms.identifier.project | Unspecified | |
rioxxterms.versionofrecord | 10.1038/s41467-017-01864-y | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2017-11-30 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Nature communications | |
pubs.issue | 1 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Endocrine Therapy Resistance | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Endocrinology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Molecular Oncology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology/Signalling & Cancer Metabolism | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology/Endocrinology (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR/Students | |
pubs.organisational-group | /ICR/Students/PhD and MPhil | |
pubs.organisational-group | /ICR/Students/PhD and MPhil/16/17 Starting Cohort | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Endocrine Therapy Resistance | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Endocrinology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Molecular Oncology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology/Signalling & Cancer Metabolism | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology/Endocrinology (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR/Students | |
pubs.organisational-group | /ICR/Students/PhD and MPhil | |
pubs.organisational-group | /ICR/Students/PhD and MPhil/16/17 Starting Cohort | |
pubs.publication-status | Published | |
pubs.volume | 8 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Endocrine Therapy Resistance | |
icr.researchteam | Molecular Oncology | |
icr.researchteam | Signalling & Cancer Metabolism | |
icr.researchteam | Endocrinology | |
dc.contributor.icrauthor | Martin, Lesley-Ann | |
dc.contributor.icrauthor | Schuster, Eugene | |
dc.contributor.icrauthor | Pancholi, Sunil | |
dc.contributor.icrauthor | Nikitorowicz-Buniak, Joanna | |
dc.contributor.icrauthor | Turgeon, Marc-Olivier | |
dc.contributor.icrauthor | Poulogiannis, Georgios | |
dc.contributor.icrauthor | Gao, Qiong | |
dc.contributor.icrauthor | Garcia-Murillas, Isaac | |
dc.contributor.icrauthor | Turner, Nicholas | |